Pharmacorp Rx Inc. PCRX
TSXV · Canada · Finance
CAD 0.3900-0.02 (-4.88%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Acquisition of a PharmaChoice Canada-bannered pharmacy in Western Canada completed at a purchase price of $1,300,000, subject to customary post-closing adjustmentsThe acquisition increases PharmaCorp’s operating network to 17 pharmaciesPreviously announced purchase of the prescription files of an I.D.A.-bannered pharmacy in Western Canada completed at a purchase price of $475,000, subject to customary post-closing adjustmentsCanadian Imperial Bank of Commerce acquisition facility increased by $1
SASKATOON, Saskatchewan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (TSXV: PCRX) (“PharmaCorp” or the “Corporation”) today announced changes to its Board of Directors, Board committee leadership and Corporate Secretary as the Corporation prepares for its 2026 Annual General and Special Meeting of Security Holders (the “2026 AGSM”). Effective August 31, 2026, Calvin Leroux will step down as a director of PharmaCorp and as Chair of the Corporation’s Corporate Governance and Compensation
Second quarter 2026 revenue up 75.8% compared to the second quarter of 2025Second quarter 2026 gross profit increased 78.2% compared to the second quarter of 2025Second quarter same-store sales were up 3.8%, and same-store prescription sales were up 5.2%, both compared to the second quarter of 2025 SASKATOON, Saskatchewan, Aug. 20, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy services and consolidation platform, today reported i
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.